X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4) 4
antineoplastic agents (3) 3
article (3) 3
chronic myelogenous leukemia (3) 3
fusion proteins, bcr-abl - genetics (3) 3
humans (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - genetics (3) 3
oncology (3) 3
antimitotic agents (2) 2
antineoplastic agents - therapeutic use (2) 2
cancer (2) 2
dasatinib (2) 2
disease-free survival (2) 2
hematology (2) 2
hematology, oncology and palliative medicine (2) 2
hemic and lymphatic diseases (2) 2
kaplan-meier estimate (2) 2
leukemia (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - pathology (2) 2
nilotinib (2) 2
philadelphia chromosome (2) 2
product development (2) 2
protein kinase inhibitors - therapeutic use (2) 2
therapy (2) 2
treatment outcome (2) 2
tyrosine kinase inhibitor (2) 2
3122 cancers (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
acquired drug resistance (1) 1
activation (1) 1
acute myeloid leukemia (1) 1
administration, oral (1) 1
adolescent (1) 1
adult (1) 1
aged (1) 1
aged, 80 and over (1) 1
analysis (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - chemistry (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
australia (1) 1
bcr-abl (1) 1
bcr-abl mutations (1) 1
bcr-abl transcripts (1) 1
bcr-abl1 transcript (1) 1
benzamides (1) 1
berlin (1) 1
biomedical sciences (1) 1
biomedicinsk vetenskap (1) 1
bosutinib (1) 1
brazil (1) 1
canada (1) 1
cancer and oncology (1) 1
cancer och onkologi (1) 1
cancer research (1) 1
cardiovascular disease (1) 1
catalytic domain (1) 1
cell biology (1) 1
chromosomes (1) 1
chronic myeloid leukemia (1) 1
chronic myeloid-leukemia (1) 1
chronic phase (1) 1
clinical medicine (1) 1
clinical trials (1) 1
control inhibitor dcc-2036 (1) 1
coronary vessels (1) 1
correlate (1) 1
dasatinib bms-354825 (1) 1
diagnosis (1) 1
discontinuation (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
drug resistance, neoplasm (1) 1
drug resistance, neoplasm - genetics (1) 1
drug-related side effects and adverse reactions - classification (1) 1
drug-related side effects and adverse reactions - pathology (1) 1
early molecular response (1) 1
europe (1) 1
fda approval (1) 1
female (1) 1
follow-up (1) 1
france (1) 1
fusion proteins, bcr-abl (1) 1
fusion proteins, bcr-abl - antagonists & inhibitors (1) 1
fusion proteins, bcr-abl - chemistry (1) 1
fusion proteins, bcr-abl - metabolism (1) 1
genetic aspects (1) 1
germany (1) 1
half (1) 1
harmonizing current methodology (1) 1
hypotheses (1) 1
imatinib (1) 1
imatinib mesylate (1) 1
imatinib mesylate - administration & dosage (1) 1
imatinib mesylate - adverse effects (1) 1
imatinib-mesylate (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Cancer Cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 428 - 442
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2002, Volume 118, Issue 4, p. 1048
Journal Article
Leukemia Research, ISSN 0145-2126, 1991, Volume 15, pp. 34 - 34
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.